Theoretically, IL-4Rα inhibition may reduce type-2 cytokine–mediated tumor-promoting immune suppression, but it could also alter protective immune surveillance, potentially impacting infection risk or anti-tumor immunity in immunocompromised hosts [20]. This evidence concerns the gene IL4R and neoplasm.